Choose Your Country or Region

Ganciclovir sodium

CMV inhibitor

Catalog No.S5065 Purity:99.96%

research use only

Ganciclovir Sodium (RS-21592, Cytovene IV, BW 759, 2'-Nor-2'-deoxyguanosine) is the sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV).

Ganciclovir sodium Chemical Structure

Molecular Weight: 277.21

Purity & Quality Control

Batch: Purity: 99.96%

99.96

Ganciclovir sodium Related Products

Related Targets	HCMV	Click to Expand
Related Products	Valaciclovir HCl Bisindolylmaleimide IV	Click to Expand
Related Compound Libraries	Anti-infection Compound Library Antibiotics compound Library Antiviral Compound Library Anti-parasitic Compound Library Gut Microbial Metabolite Library	Click to Expand

Cell Culture and Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
CEM	Cytotoxicity assay		Cytotoxicity against CEM cells, CC50 = 5 μM.	15615545
bone marrow cells	Cytotoxicity assay	15 days	Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days, CC50 = 30 μM.	17329103
RG2TK+	Cytotoxicity assay	72 hrs	Cytotoxicity against HSV1-tk gene overexpressing RG2TK+ cells after 72 hrs by MTT assay, CC50 = 5.86 μM.	18800764
HFF	Function assay		Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells, EC50 = 0.5 μM.	8394933
Vero	Function assay		Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%, EC50 = 0.23 μM.	11585457
MRC-5	Function assay		Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells., EC50 = 9.4 μM.	12723951
HEL	Function assay		Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50 = 0.06 μM.	14643328
HFF	Function assay		Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay, EC50 = 2.1 μM.	15615545
HFF	Function assay		Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay, EC50 = 2.2 μM.	15615545
H-1	Function assay		Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50 = 5 μM.	15615545
H-1	Function assay		Effective concentration required to inhibit Epstein-barr virus replication in H-1 cells in DNA hybridization assay, EC50 = 5 μM.	15634003
Hel	Function assay		Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells, EC50 = 0.06 μM.	15658858
HEL	Antiviral assay		Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.06 μM.	16392791
HEL	Antiviral assay		Antiviral activity against HSV2 G in HEL cells, EC50 = 0.06 μM.	16392791
HFF	Function assay		Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay, EC50 = 0.15 μM.	17004726
HFF	Function assay		Inhibition of HCMV towne replication in HFF cells by plaque reduction assay, EC50 = 1.8 μM.	17004726
H1	Function assay		Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50 = 5 μM.	17004726
HEL	Antiviral assay		Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.019 μM.	17181162
HEL	Antiviral assay		Antiviral activity against HSV2 in HEL cells, EC50 = 0.032 μM.	17181162
HEL	Antiviral assay		Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.48 μM.	17181162
CCL81	Antiviral assay		Antiviral activity against HSV2 in CCL81 cells, EC50 = 1.5 μM.	17188402
CCL81	Antiviral assay		Antiviral activity against HSV1 in CCL81 cells, EC50 = 1.5 μM.	17188402
Vero	Antiviral assay	36 to 48 hrs	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 0.7 μM.	17438061
Vero	Antiviral assay	36 to 48 hrs	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 14.5 μM.	17438061
Vero	Antiviral assay	36 to 48 hrs	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 19.2 μM.	17438061
Vero	Antiviral assay	36 to 48 hrs	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 23.5 μM.	17438061
HEL	Antiviral assay		Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation, EC50 = 2.75 μM.	17518459
HEL	Antiviral assay		Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation, EC50 = 6.3 μM.	17518459
HEL	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days, EC50 = 1.3 μM.	17539622
HEL	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days, EC50 = 4.8 μM.	17539622
HEL	Antiviral assay	5 days	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days, EC50 = 2.3 μM.	17622128
HEL	Antiviral assay	7 days	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50 = 5.1 μM.	17622128
HEL	Antiviral assay	7 days	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50 = 8.7 μM.	17622128
HEL	Antiviral assay	7 days	Antiviral activity against CMV Davis in human HEL cells after 7 days, EC50 = 2.6 μM.	17672445
HEL	Antiviral assay	7 days	Antiviral activity against CMV AD169 in human HEL cells after 7 days, EC50 = 6.5 μM.	17672445
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50 = 1.1 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 2.6 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 2.7 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 3.5 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 3.9 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 6.1 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 6.6 μM.	17709468
HFF	Antiviral assay		Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 8.4 μM.	17709468
HEL	Antiviral assay	3 days	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50 = 1.3 μM.	17961851
HEL	Antiviral assay	3 days	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50 = 4.8 μM.	17961851
HFF	Antiviral assay		Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay, EC50 = 2.5 μM.	18082410
hhTERT-BJ1	Antiviral assay	2 days	Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days, EC50 = 3 μM.	18458124
NIH 3T3	Antiviral assay	4 to 5 days	Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay, EC50 = 5.7 μM.	18458124
HEL	Antiviral assay		Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.66 μM.	19226140
HEL	Antiviral assay		Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.69 μM.	19226140
HEL	Antiviral assay		Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.7 μM.	19226140
HEL	Antiviral assay		Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 1.2 μM.	19226140
HEL	Antiviral assay	7 days	Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50 = 2 μM.	19226140
HEL	Antiviral assay		Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 2.6 μM.	19226140
HEL	Antiviral assay		Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 3.5 μM.	19226140
HEL	Antiviral assay	7 days	Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50 = 3.6 μM.	19226140
HEL	Antiviral assay		Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 4 μM.	19226140
HEL	Antiviral assay		Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 4.3 μM.	19226140
HEL	Antiviral assay		Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.02 μM.	19281225
HEL	Antiviral assay		Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.2 μM.	19281225
feline FRCK	Antiviral assay		Antiviral activity against Feline herpesvirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity, EC50 = 1.2 μM.	19281225
HEL	Antiviral assay		Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 9 μM.	19281225
HEL	Antiviral assay	5 days	Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50 = 0.59 μM.	19339082
HEL	Antiviral assay	5 days	Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days, EC50 = 1.1 μM.	19339082
HEL	Antiviral assay	5 days	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50 = 2.5 μM.	19339082
HEL	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50 = 2.5 μM.	19339082
HEL	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50 = 12.6 μM.	19339082
foreskin fibroblast cells	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM.	19397271
foreskin fibroblast cells	Antiviral assay		Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay, EC50 = 1.2 μM.	19397271
embryonic fibroblast cells	Antiviral assay		Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay, EC50 = 5.5 μM.	19397271
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
Vero	Antiviral assay		Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM.	19858259
HEL	Antiviral assay	2 to 3 days	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM.	20034711
HEL	Antiviral assay	2 to 3 days	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM.	20034711
HEL	Antiviral assay	2 to 3 days	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM.	20034711
CRFK	Antiviral assay		Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay, EC50 = 2.6 μM.	20034711
HS27	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 0.32 μM.	20047911
MRC5	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 1.65 μM.	20047911
HEL299	Antiviral assay	7 days	Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 2.39 μM.	20047911
HEL	Antiviral assay	7 days	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 0.05 μM.	21128666
HEL	Antiviral assay	7 days	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 0.08 μM.	21128666
HEL	Antiviral assay	7 days	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 3 μM.	21128666
HEL	Antiviral assay	7 days	Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 5.2 μM.	21128666
HEL	Antiviral assay		Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.01 μM.	21232828
HEL	Antiviral assay		Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM.	21232828
HEL	Antiviral assay		Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.1 μM.	21232828
HFF	Antiviral assay	1 hr	Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50 = 0.04 μM.	21376429
HEL	Antiviral assay		Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.027 μM.	21565516
HEL	Antiviral assay		Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.03 μM.	21565516
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 6 μM.	21565516
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 6.54 μM.	21565516
CRFK	Antiviral assay		Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity, EC50 = 8.1 μM.	21565516
HEL	Antiviral assay		Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 15.7 μM.	21565516
HEL	Antiviral assay	4 days	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.03 μM.	21696963
HEL	Antiviral assay	4 days	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.03 μM.	21696963
HEL	Antiviral assay	4 days	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.8 μM.	21696963
HEL	Antiviral assay	4 days	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50 = 0.02 μM.	22459876
HEL	Antiviral assay	4 days	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50 = 0.03 μM.	22459876
HEL	Antiviral assay	4 days	Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50 = 1.65 μM.	22459876
HEL	Antiviral assay	4 days	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50 = 1.65 μM.	22459876
CRFK	Antiviral assay	4 days	Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay, EC50 = 4.1 μM.	22459876
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50 = 7.1 μM.	22578783
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50 = 7.5 μM.	22578783
HEL	Antiviral assay		Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay, EC50 = 0.027 μM.	22858222
HEL	Antiviral assay		Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay, EC50 = 0.029 μM.	22858222
CRFK	Antiviral assay		Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay, EC50 = 1.15 μM.	22858222
HEL	Antiviral assay		Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay, EC50 = 5.9 μM.	22858222
HEL	Antiviral assay		Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay, EC50 = 9.1 μM.	22858222
HEL	Antiviral assay		Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay, EC50 = 14.7 μM.	22858222
CRFK	Antiviral assay	3 days	Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as inhibition of virus-induced cytopathicity after 3 days, EC50 = 1.2 μM.	23047229
HEL	Antiviral assay		Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.013 μM.	23099097
HEL	Antiviral assay		Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.015 μM.	23099097
HEL	Antiviral assay		Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 4 μM.	23099097
HEL	Antiviral assay		Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 0.01 μM.	23795238
HEL	Antiviral assay		Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 0.01 μM.	23795238
HEL	Antiviral assay		Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 1 μM.	23795238
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM.	23811093
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM.	23811093
HEL	Antiviral assay		Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 4 μM.	23811093
CRFK	Antiviral assay		Antiviral activity against feline herpesvirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay, EC50 = 4.1 μM.	23811093
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation, EC50 = 5.98 μM.	23811093
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation, EC50 = 7.87 μM.	23811093
HEL	Antiviral assay		Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after, EC50 = 8.2 μM.	23911854
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation, EC50 = 0.38 μM.	23911856
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.9 μM.	23911856
CRFK	Antiviral assay		Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay, EC50 = 0.9 μM.	23911856
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation, EC50 = 3.1 μM.	23911856
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.02 μM.	26001344
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM.	26001344
HEL	Antiviral assay		Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.5 μM.	26001344
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 6.3 μM.	26001344
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 7.1 μM.	26001344
HEL	Antiviral assay	7 days	Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50 = 4.72 μM.	26291038
HEL	Antiviral assay	7 days	Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50 = 6.12 μM.	26291038
HEL	Antiviral assay		Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation, EC50 = 7.8 μM.	26443550
HEL	Antiviral assay		Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation, EC50 = 13.9 μM.	26443550
Vero	Antiviral assay	3 days	Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 0.9 μM.	26460883
Vero	Antiviral assay	3 days	Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 1.4 μM.	26460883
Vero	Antiviral assay	3 days	Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 2.14 μM.	26460883
Vero	Antiviral assay	3 days	Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 11.1 μM.	26460883
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus AD169 infected in HEL cells, EC50 = 0.25 μM.	27128178
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells, EC50 = 0.4 μM.	27128178
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 0.03 μM.	27639368
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 0.09 μM.	27639368
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 2.1 μM.	27639368
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 3.1 μM.	27639368
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.032 μM.	27750154
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.055 μM.	27750154
HEL	Antiviral assay		Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 4 μM.	27750154
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation, EC50 = 6.5 μM.	27750154
HEL	Antiviral assay		Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation, EC50 = 14.9 μM.	27750154
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 8.7 μM.	28682067
HEL	Antiviral assay		Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 16.5 μM.	28682067
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.03 μM.	28757102
HEL	Antiviral assay		Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM.	28757102
HEL	Antiviral assay		Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.1 μM.	28757102
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 2.96 μM.	28757102
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 6.79 μM.	28757102
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.03 μM.	28829913
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM.	28829913
HEL	Antiviral assay		Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 4.3 μM.	28829913
HEL	Antiviral assay		Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 7.3 μM.	28829913
HEL	Antiviral assay		Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 7.4 μM.	28829913
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect, EC50 = 4.05 μM.	29407990
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect, EC50 = 5.63 μM.	29407990
HEL	Antiviral assay	2 to 3 days	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 0.019 μM.	29550734
HEL	Antiviral assay	2 to 3 days	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 0.045 μM.	29550734
HEL	Antiviral assay	2 to 3 days	Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 3.91 μM.	29550734
HEL	Antiviral assay	6 to 7 days	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50 = 4.83 μM.	29550734
HEL	Antiviral assay	6 to 7 days	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50 = 6.46 μM.	29550734
HEL	Antiviral assay	2 to 3 days	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50 = 0.051 μM.	29670705
HEL	Antiviral assay	2 to 3 days	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50 = 0.057 μM.	29670705
HEL	Antiviral assay	6 to 7 days	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50 = 3.31 μM.	29670705
HEL	Antiviral assay	6 to 7 days	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50 = 7.41 μM.	29670705
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.02 μM.	29880251
HEL	Antiviral assay		Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.02 μM.	29880251
HEL	Antiviral assay		Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.8 μM.	29880251
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 2.29 μM.	29880251
HEL	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 11.43 μM.	29880251
HELF	Antiviral assay		Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.03 μM.	30098481
HELF	Antiviral assay		Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.03 μM.	30098481
HELF	Antiviral assay		Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.5 μM.	30098481
HELF	Antiviral assay		Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 6.52 μM.	30098481
HELF	Antiviral assay		Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 11.75 μM.	30098481
HEL	Antiviral assay	3 days	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.01 μM.	30286952
HEL	Antiviral assay	3 days	Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.01 μM.	30286952
HEL	Antiviral assay	3 days	Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.2 μM.	30286952
HFF	Antiviral assay	5 to 7 days	Antiviral activity against HCMV infected HFF cells after 5 to 7 days by viral yield assay, EC99.9 = 5 μM.	17329103
MRC-5	Antiviral assay		In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain), IC50 = 4 μM.	1323678
BSC-1	Antiviral assay		Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50 = 3 μM.	2913300
HEL	Function assay		Inhibition of human CMV DNA synthesis in CMV-infected HEL cells., IC50 = 0.5 μM.	7752205
HEL	Function assay		Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR., IC50 = 7 μM.	7752205
BSC-1	Antiviral assay		In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells., IC50 = 3.5 μM.	9057865
HFF	Antiviral assay		In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells., IC50 = 7.4 μM.	9057865
HFF	Antiviral assay		Antiviral activity was determined by the HCMV plaque assay using HFF cells, IC50 = 7.7 μM.	9057866
HFF	Function assay		Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay, IC50 = 2.6 μM.	9438017
MEF	Function assay		Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay, IC50 = 3.4 μM.	9438017
HFF	Function assay		Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM.	9438017
MRC-5	Function assay		Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells, IC50 = 6.3 μM.	9836613
BSC-1	Antiviral assay		Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells, IC50 = 3.5 μM.	10882370
HFF	Antiviral assay		Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells, IC50 = 7.4 μM.	10882370
BSC-1	Function assay		ELISA assay was performed using BSC-1 cells to determine activity against HSV-1, IC50 = 3.5 μM.	10882372
HFF	Antiviral assay		Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells, IC50 = 7.4 μM.	10882372
HFF	Function assay		Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells, IC50 = 4.1 μM.	10882374
HFF	Function assay		Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells, IC50 = 4.5 μM.	10882374
HFF	Function assay		Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells, IC50 = 7.4 μM.	10882374
HFF	Function assay		Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells, IC50 = 7.4 μM.	10882375
MRC-5	Function assay		Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells, IC50 = 5.9 μM.	10966740
MRC5	Function assay		Inhibitory concentration against Davis strain of HCMV in MRC5 cells, IC50 = 1.4 μM.	11454465
MRC5	Function assay		Inhibitory concentration against Towne strain of HCMV in MRC5 cells, IC50 = 1.5 μM.	11454465
MRC5	Function assay		Inhibitory concentration against 2599R strain of HCMV in MRC5 cells, IC50 = 1.6 μM.	11454465
MRC5	Function assay		Inhibitory concentration against AD169 strain of HCMV in MRC5 cells, IC50 = 3 μM.	11454465
BSC-1	Function assay		Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM.	15509174
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM.	15509174
BSC-1	Function assay		Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM.	15509175
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM.	15509175
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM.	15509176
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM.	15509176
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM.	15509176
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 2.5 μM.	15509176
BSC-1	Function assay		Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM.	15509176
HFF	Function assay		Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM.	15509176
foreskin fibroblast cells	Antiviral assay	1 hr	Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50 = 0.8 μM.	16134946
foreskin fibroblast cells	Antiviral assay	1 hr	Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50 = 0.8 μM.	16134946
foreskin fibroblast cells	Antiviral assay		Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO, IC50 = 1.3 μM.	16134946
bone marrow cells	Cytotoxicity assay		Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50 = 30 μM.	16814545
HFF	Antiviral assay		Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay, IC50 = 1.3 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50 = 1.4 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay, IC50 = 1.4 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV AD169 in HFF cells by PRA, IC50 = 1.9 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2291 in HFF cells by PRA, IC50 = 4.1 μM.	17043128
MRC5	Antiviral assay		Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50 = 4.9 μM.	17043128
MRC5	Antiviral assay		Antiviral activity against Human CMV T2296 in MRC5 cells by PRA, IC50 = 5.4 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay, IC50 = 5.6 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay, IC50 = 7.1 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2293 in HFF cells by PRA, IC50 = 10 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2311 in HFF cells by PRA, IC50 = 12.4 μM.	17043128
MRC5	Antiviral assay		Antiviral activity against Human CMV T2287 in MRC5 cells by PRA, IC50 = 30.1 μM.	17043128
HFF	Antiviral assay		Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay, IC50 = 30.2 μM.	17043128
HFF	Antiviral assay		Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay, IC50 = 3 μM.	17161946
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK, IC50 = 0.0019 μM.	17181158
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.018 μM.	17181158
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.033 μM.	17181158
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.041 μM.	17181158
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.05 μM.	17181158
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.081 μM.	17181158
OST TK-cells	Cytotoxicity assay		Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.11 μM.	17181158
MRC5	Antiviral assay		Antiviral activity against HCMV in MRC5 cells by plaque reduction assay, IC50 = 0.91 μM.	17239594
HFF	Antiviral assay	5 days	Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay, IC50 = 1 μM.	17329103
HFF	Antiviral assay		Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay, IC50 = 1.3 μM.	17434304
MCA-TK	Cytotoxicity assay		Cytotoxicity against MCA-TK cells, IC50 = 0.15 μM.	17960926
HFF	Antiviral assay		Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay, IC50 = 3.22 μM.	19010684
HFF	Antiviral assay		Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay, IC50 = 16.4 μM.	19010684
HFF	Antiviral assay		Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay, IC50 = 1.3 μM.	20167488
HFF	Function assay		Inhibition of HCMV DNA polymerase infected in HFF cells, IC50 = 1.3 μM.	20403696
HFF	Antiviral assay	10 days	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days, IC50 = 3 μM.	21641218
HFF	Antiviral assay	10 days	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay, IC50 = 0.14 μM.	21812420
HFF	Antiviral assay	8 days	Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay, IC50 = 2.1 μM.	22607883
HFF	Function assay		In vitro reduction in yield of Towne strain of HCMV in HFF (human fibroblast) cells., IC90 = 1.6 μM.	9057865
HFF	Function assay		Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by yield reduction assay, IC90 = 1.6 μM.	9438017
HFF	Antiviral assay		Antiviral activity against towne strain HCMV was determined by yield reduction assay in duplicate wells using HFF cells, IC90 = 1.6 μM.	10882370
HFF	Antiviral assay		Antiviral activity against HCMV was determined by yield reduction assay using HFF cells, IC90 = 1.6 μM.	10882372
HFF	Function assay		Compound was tested for antiviral activity against Towne strain of HCMV in a yield reduction assay using HFF cells, IC90 = 1.6 μM.	10882374
HFF	Function assay		Compound was tested for antiviral activity against wild-type AD169 strain of HCMV in yield reduction assay using HFF cells, IC90 = 3.3 μM.	10882374
HFF	Function assay		Compound was tested for antiviral activity against 2916 AD169 strain of HCMV in yield reduction assay using HFF cells, IC90 = 3.6 μM.	10882374
HFF	Function assay		Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by yield reduction assay using HFF cells, IC90 = 1.6 μM.	10882375
vero	Antiviral assay		In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture, ID50 = 0.3 μM.	2993615
vero	Antiviral assay		In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells., ID50 = 1.3 μM.	2993615
HCMV AD 169	Antiviral assay		In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells., ID50 = 6 μM.	2993615
Vero	Antiviral assay		In vitro antiviral activity was measured against HSV-1(F) in Vero cells, ID50 = 0.2 μM.	3009811
Vero	Antiviral assay		In vitro antiviral activity was measured against HSV-2(G) in Vero cells, ID50 = 1.6 μM.	3009811
MRC5	Antiviral assay		In vitro antiviral activity was measured against HCMV(AD-169) in MRC5 cells, ID50 = 5 μM.	3009811
Vero	Antiviral assay		In vitro antiviral activity was measured against HSV-1 (F delta 305) in Vero cells, ID50 = 10 μM.	3009811
Vero	Antiviral assay		Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells, ID50 = 0.2 μM.	3016263
vero	Antiviral assay		Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain, ID50 = 0.2 μM.	3871860
E6SM	Antiviral assay		Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells, MIC = 0.096 μM.	17092728
E6SM	Antiviral assay		Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells, MIC = 0.096 μM.	17092728
E6SM	Antiviral assay		Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells, MIC = 0.8 μM.	17092728
HEL	Antiviral assay		Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC = 0.0064 μM.	17672445
HEL	Antiviral assay		Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC = 0.032 μM.	17672445
neural precursor cells	Function assay		Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	17417631
A673	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Saos-2	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
BT-12	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
MG 63 (6-TG R)	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
OHS-50	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
SJ-GBM2	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
Click to View More Cell Line Experimental Data

Mechanism of Action

Description	Ganciclovir Sodium (RS-21592, Cytovene IV, BW 759, 2'-Nor-2'-deoxyguanosine) is the sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV).

In vitro
In vitro	Ganciclovir Sodium (RS-21592, Cytovene IV, BW 759, 2'-Nor-2'-deoxyguanosine) is the sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV).
Cell Research	Cell lines	TM cells
	Concentrations	0, 10, 100 μM
	Incubation Time	1, 3, 5 and 7 days
	Method	Cells were treated with indicated concentration of drug for several days.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06407232	Not yet recruiting	Cytomegalovirus Infections\|Kidney Transplant Infection\|Pancreas Transplant	University of Wisconsin Madison\|Merck Sharp & Dohme LLC	May 2024	Phase 3
NCT06057194	Not yet recruiting	Infections Cytomegalovirus	Maimónides Biomedical Research Institute of Córdoba\|MERCK SHARP & DOHME DE ESPAÑA S.A.	October 2023	Phase 2
NCT04706507	Recruiting	Acute Respiratory Failure	Fred Hutchinson Cancer Center\|National Heart Lung and Blood Institute (NHLBI)	June 29 2021	Phase 3
NCT04478474	Completed	Cytomegalovirus Infections	New York Medical College\|Merck Sharp & Dohme LLC	September 15 2020	--
NCT03698435	Unknown status	Cytomegalovirus Infections	University Medical Center Groningen	May 25 2018	--

References
https://pubmed.ncbi.nlm.nih.gov/31216320/ https://pubmed.ncbi.nlm.nih.gov/35708907/

References

https://pubmed.ncbi.nlm.nih.gov/31216320/
https://pubmed.ncbi.nlm.nih.gov/35708907/

Chemical Information

Molecular Weight	277.21	Formula	C₉H₁₂N₅NaO₄
CAS No.	107910-75-8	SDF	--
Synonyms	RS-21592 sodium, Cytovene IV sodium, BW 759 sodium, 2'-Nor-2'-deoxyguanosine sodium
Smiles	C1=NC2=C(N1COC(CO)CO)N=C(N=C2[O-])N.[Na+]

Storage and Stability

Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
			1 month-20°Cin solvent

In vitro
Batch:

DMSO : 8 mg/mL ( (28.85 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 6 mg/mL

Ethanol : Insoluble

Molecular Weight Calculator

In vivo Batch: Add solvents to the product individually and in order.				In vivo Formulation Calculator
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):